NGL Fine-Chem Limited (NGLFINE.NS)
INR 1102.5
(-2.0%)
INR 1102.5
(-2.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 7.44 Million INR | -64.07% |
| 2022 | 20.73 Million INR | -39.67% |
| 2021 | 34.36 Million INR | -43.96% |
| 2020 | 61.31 Million INR | -26.35% |
| 2019 | 83.24 Million INR | 3.97% |
| 2018 | 80.06 Million INR | -35.22% |
| 2017 | 123.6 Million INR | 30.68% |
| 2016 | 94.58 Million INR | 2967.44% |
| 2015 | 3.08 Million INR | -80.37% |
| 2014 | 15.7 Million INR | -53.3% |
| 2013 | 33.62 Million INR | 6.59% |
| 2012 | 31.54 Million INR | -16.34% |
| 2011 | 37.71 Million INR | -40.21% |
| 2010 | 63.07 Million INR | 24.93% |
| 2009 | 50.49 Million INR | 21.96% |
| 2008 | 41.39 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 7.44 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 7.44 Million INR | -64.07% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 11.66 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 20.73 Million INR | 0.0% |
| 2022 FY | 20.73 Million INR | -39.67% |
| 2022 Q2 | 23.44 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 34.36 Million INR | 0.0% |
| 2021 Q2 | 42.26 Million INR | 0.0% |
| 2021 FY | 34.36 Million INR | -43.96% |
| 2020 Q2 | 89.34 Million INR | 0.0% |
| 2020 FY | 61.31 Million INR | -26.35% |
| 2020 Q4 | 61.31 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q2 | 110.75 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 83.24 Million INR | 3.97% |
| 2019 Q4 | 83.24 Million INR | 0.0% |
| 2018 FY | 80.06 Million INR | -35.22% |
| 2018 Q4 | 80.06 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 99.44 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 123.6 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 123.6 Million INR | 30.68% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 108.43 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 94.58 Million INR | 2967.44% |
| 2016 Q4 | 94.58 Million INR | 0.0% |
| 2016 Q2 | 24.71 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 10.21 Million INR | 0.0% |
| 2015 FY | 3.08 Million INR | -80.37% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 3.08 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 FY | 15.7 Million INR | -53.3% |
| 2014 Q4 | 15.7 Million INR | 0.0% |
| 2014 Q2 | 25.41 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 33.62 Million INR | 6.59% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 33.11 Million INR | 0.0% |
| 2013 Q4 | 33.62 Million INR | 0.0% |
| 2012 Q4 | 31.54 Million INR | 0.0% |
| 2012 FY | 31.54 Million INR | -16.34% |
| 2011 Q4 | 37.71 Million INR | 0.0% |
| 2011 FY | 37.71 Million INR | -40.21% |
| 2010 FY | 63.07 Million INR | 24.93% |
| 2009 FY | 50.49 Million INR | 21.96% |
| 2008 Q4 | 41.39 Million INR | 0.0% |
| 2008 FY | 41.39 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott India Limited | 367.6 Million INR | 97.974% |
| Cipla Limited | 2.25 Billion INR | 99.67% |
| Gland Pharma Limited | 1.06 Billion INR | 99.301% |
| GlaxoSmithKline Pharmaceuticals Limited | 64.69 Million INR | 88.487% |
| Kopran Limited | 166.02 Million INR | 95.514% |
| Marksans Pharma Limited | 1.9 Billion INR | 99.608% |
| Pfizer Limited | 543.5 Million INR | 98.63% |
| Sanofi India Limited | 139 Million INR | 94.642% |
| SMS Pharmaceuticals Limited | 1.22 Billion INR | 99.39% |
| TTK Healthcare Limited | 7.98 Million INR | 6.748% |